The Value of Neutrophil-to-Lymphocyte Ratio in Predicting Mortality After Transjugular Intrahepatic Portosystemic Shunt Placement

References

• de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi:10.1016/j.jhep.2021.12.022
   PubMed Web of Science ®Google Scholar
• Lv Y, Chen H, Luo B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial. Hepatology. 2022;76(3):676–688. doi:10.1002/hep.32453
   PubMed Web of Science ®Google Scholar
• Lv Y, Chen H, Luo B, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7(8):736–746. doi:10.1016/S2468-1253(22)00087-5
   PubMedGoogle Scholar
• Song J, Wang X, Yan Y, et al. MELD 3.0 score for predicting survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt creation. Dig Dis Sci. 2023;68(7):3185–3192. doi:10.1007/s10620-023-07834-3
   PubMedGoogle Scholar
• Li WC, Zhong BY, Zhang S, et al. Emergent transjugular intrahepatic portosystemic shunt as a first-line therapy in patients with cirrhosis with acute gastroesophageal variceal hemorrhage. J Vasc Interv Radiol. 2023;34(3):344–350. doi:10.1016/j.jvir.2022.11.015
   PubMedGoogle Scholar
• Liu J, Ma J, Yang C, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement. Radiology. 2022;303(3):711–719. doi:10.1148/radiol.211172
   PubMedGoogle Scholar
• Alatzides GL, Haubold J, Steinberg HL, et al. Adipopenia in body composition analysis: a promising imaging biomarker and potential predictive factor for patients undergoing transjugular intrahepatic portosystemic shunt placement. Br J Radiol. 2023;96(1146):20220863. doi:10.1259/bjr.20220863
   PubMedGoogle Scholar
• Sun SH, Eche T, Dorczynski C, et al. Predicting death or recurrence of portal hypertension symptoms after TIPS procedures. Eur Radiol. 2022;32(5):3346–3357. doi:10.1007/s00330-021-08437-0
   PubMedGoogle Scholar
• Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–871. doi:10.1053/he.2000.5852
   PubMed Web of Science ®Google Scholar
• Leise MD, Kim WR, Kremers WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140(7):1952–1960. doi:10.1053/j.gastro.2011.02.017
   PubMedGoogle Scholar
• Bettinger D, Sturm L, Pfaff L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol. 2021;74(6):1362–1372. doi:10.1016/j.jhep.2021.01.023
   PubMed Web of Science ®Google Scholar
• Peng Y, Li Y, He Y, et al. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review. Expert Rev Gastroenterol Hepatol. 2018;12(5):503–513. doi:10.1080/17474124.2018.1463158
   PubMed Web of Science ®Google Scholar
• Rice J, Dodge JL, Bambha KM, et al. Neutrophil-to-lymphocyte ratio associates independently with mortality in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(11):1786–1791. doi:10.1016/j.cgh.2018.04.045
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang X, Chen Q, et al. A novel neutrophil-to-lymphocyte ratio and sarcopenia based TACE-predict model of hepatocellular carcinoma patients. J Hepatocell Carcinoma. 2023;10:659–671. doi:10.2147/JHC.S407646
   PubMed Web of Science ®Google Scholar
• Leithead JA, Rajoriya N, Gunson BK, et al. Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation. Liver Int. 2015;35(2):502–509. doi:10.1111/liv.12688
   PubMed Web of Science ®Google Scholar
• Li J, Chen Q, Luo X, et al. Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population. J Clin Lab Anal. 2015;29(6):437–443. doi:10.1002/jcla.21791
   PubMed Web of Science ®Google Scholar
• Liu S, Zheng H, Zhu X, et al. Neutrophil-to-lymphocyte ratio is associated with diabetic peripheral neuropathy in type 2 diabetes patients. Diabet Res Clin Pract. 2017;130:90–97. doi:10.1016/j.diabres.2017.05.008
   PubMed Web of Science ®Google Scholar
• Tang HH, Zhang ZC, Zhao ZL, et al. Large paraumbilical vein shunts increase the risk of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. J Clin Med. 2022;12(1):158. doi:10.3390/jcm12010158
   PubMedGoogle Scholar
• Biyik M, Ucar R, Solak Y, et al. Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2013;25(4):435–441. doi:10.1097/MEG.0b013e32835c2af3
   PubMed Web of Science ®Google Scholar
• Kalra A, Wedd JP, Bambha KM, et al. Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis. Liver Transpl. 2017;23(2):155–165. doi:10.1002/lt.24702
   PubMed Web of Science ®Google Scholar
• Sun J, Guo H, Yu X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure. BMC Gastroenterol. 2021;21(1):422. doi:10.1186/s12876-021-02007-w
   PubMedGoogle Scholar
• Janka T, Tornai D, Papp M, et al. The value of neutrophil-to-lymphocyte ratio to identify bacterial infection and predict short-term mortality in patients with acutely decompensated cirrhosis. Diagnostics. 2023;13(18):2954. doi:10.3390/diagnostics13182954
   Google Scholar
• Qu Z, Lu YJ, Feng JW, et al. Preoperative prognostic nutritional index and neutrophil-to-lymphocyte ratio predict survival outcomes of patients with hepatocellular carcinoma after curative resection. Front Oncol. 2021;11:823054. doi:10.3389/fonc.2021.823054
   PubMedGoogle Scholar
• Ochi H, Kurosaki M, Joko K, et al. Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Hepatol Res. 2023;53(1):61–71. doi:10.1111/hepr.13836
   PubMedGoogle Scholar
• Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474–488. doi:10.4149/BLL_2021_078
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26–S34. doi:10.1097/CCM.0b013e3181c98d21
   PubMed Web of Science ®Google Scholar
• Stöth M, Freire Valls A, Chen M, et al. Splenectomy reduces lung metastases and tumoral and metastatic niche inflammation. Int, J, Cancer. 2019;145(9):2509–2520. doi:10.1002/ijc.32378
   PubMed Web of Science ®Google Scholar
• Zhang W, Aryan M, Chen Z, et al. Prognostic value of neutrophil-to-lymphocyte ratio in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol. 2022;34(4):435–442. doi:10.1097/MEG.0000000000002295
   PubMedGoogle Scholar
• Saad N, Rude MK, Darcy M, et al. Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt. Ann Hepatol. 2016;15(2):215–221. doi:10.5604/16652681.1193716
   PubMedGoogle Scholar
• Vizzutti F, Celsa C, Calvaruso V, et al. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: a validated prediction model. Hepatology. 2023;77(2):476–488. doi:10.1002/hep.32704
   PubMedGoogle Scholar
• Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74(3):1611–1644. doi:10.1002/hep.32049
   PubMed Web of Science ®Google Scholar
• Mazumder NR, Celaj S, Atiemo K, et al. Liver-related mortality is similar among men and women with cirrhosis. J Hepatol. 2020;73(5):1072–1081. doi:10.1016/j.jhep.2020.04.022
   PubMedGoogle Scholar
• Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis. Gut. 2021;70(5):982–994. doi:10.1136/gutjnl-2020-320786
   PubMed Web of Science ®Google Scholar